Journal of Drug Metabolism & Toxicology
Open Access
ISSN: 2157-7609
ISSN: 2157-7609
Farhad Kamali
Newcastle University, UK
Scientific Tracks Abstracts: J Drug Metab Toxicol
Warfarin is commonly prescribed for the treatment and prevention of thromboembolic disorders. Anticoagulation response to warfarin during the initiation of therapy is variable. This is mainly due to the drug��?s narrow therapeutic window and the wide inter-individual variability in warfarin dose requirement which makes the prediction of an accurate dose for individual patients difficult despite the use of standard induction regimens and frequent INR monitoring. As a result, some patients who are sensitive to warfarin are at increased risk of bleeding due to over-dosing whereas some are at increased risk of thrombosis due to underdosing. Approximately half of the variability in warfarin dose requirement is explained by patient age, body size and CYP2C9 and VKORC1 genes. A personalized approach to warfarin dosing using genetic information has the potential to improve the safety and efficacy of anticoagulation therapy. The author will be presenting the results of prospective trials exploring the potential benefits of pharmacogenetics-based therapy and the potential for future implementation of pharmacogenetics-guided therapy in the clinic setting.
Farhad Kamali is Professor of Human & Experimental Pharmacology at the Institute of Cellular Medicine, Newcastle University, United Kingdom. He has published well over one hundred articles in peer reviewed journals as well as book chapters. He serves on the editorial board of a number of journals in the areas of clinical pharmacology, pharmacogenetics and haematology. His research focuses on the elucidation of the mechanisms of drug-induced toxicity and in particular identifying the risk factors associated with poor outcomes in anticoagulation treatment of thromboembolic disease.